Clinical Trials Browser

Active not recruiting × Interventional × aflutinib × Clear all

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04858958 2025-11-19

FAVOUR

Phase 1 Active not recruiting

NSCLC

NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Phase 2 Active not recruiting

NSCLC

NCT05607550 2025-06-22

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer